Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NMPA Approval

Irinotecan Hydrochloride Liposome Injection（Ⅱ）

Approval Number

国药准字H20230036

Company江苏恒瑞医药股份有限公司

Registration Date

January 9, 2024

Drug Information

Generic Name

盐酸伊立替康脂质体注射液(Ⅱ)

Dosage Form

注射剂

Strength

8ml：37.66mg（按C₃₃H₃₈N₄O₆计）

Drug Type

化学药品

Registration Date

January 9, 2024

Company Information

Applicant Company

Company Name江苏恒瑞医药股份有限公司

Company Address

连云港经济技术开发区黄河路38号

Manufacturing Company

Company Name江苏恒瑞医药股份有限公司

Company Address

连云港经济技术开发区临港产业区东晋路

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy